ChemoCentryx, Inc. - Product Pipeline Review - 2016

Published: Sep, 2016 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

ChemoCentryx, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'ChemoCentryx, Inc. - Product Pipeline Review - 2016', provides an overview of the ChemoCentryx, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by ChemoCentryx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of ChemoCentryx, Inc.
- The report provides overview of ChemoCentryx, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses ChemoCentryx, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features ChemoCentryx, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate ChemoCentryx, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for ChemoCentryx, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding ChemoCentryx, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
ChemoCentryx, Inc. Snapshot 6
ChemoCentryx, Inc. Overview 6
Key Facts 6
ChemoCentryx, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
ChemoCentryx, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
ChemoCentryx, Inc. - Pipeline Products Glance 13
ChemoCentryx, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
ChemoCentryx, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
ChemoCentryx, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
ChemoCentryx, Inc. - Drug Profiles 18
CCR-23G - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
CCR-93G - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
CCX-140 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
CCX-168 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
CCX-354 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CCX-507 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CCX-6239 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CCX-650 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CCX-771 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
CCX-872 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CCX-9588 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CCX-991 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule to Antagonize CXCR6 for Autoimmune, Oncology and Liver Diseases - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
vercirnon sodium - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ChemoCentryx, Inc. - Pipeline Analysis 46
ChemoCentryx, Inc. - Pipeline Products by Target 46
ChemoCentryx, Inc. - Pipeline Products by Route of Administration 48
ChemoCentryx, Inc. - Pipeline Products by Molecule Type 49
ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action 50
ChemoCentryx, Inc. - Dormant Projects 52
ChemoCentryx, Inc. - Discontinued Pipeline Products 53
Discontinued Pipeline Product Profiles 53
CCX-832 53
vercirnon sodium 53
ChemoCentryx, Inc. - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54

Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

ChemoCentryx, Inc., Key Facts 6
ChemoCentryx, Inc. - Pipeline by Indication, 2016 9
ChemoCentryx, Inc. - Pipeline by Stage of Development, 2016 11
ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2016 12
ChemoCentryx, Inc. - Phase III, 2016 13
ChemoCentryx, Inc. - Phase II, 2016 14
ChemoCentryx, Inc. - Phase I, 2016 15
ChemoCentryx, Inc. - Preclinical, 2016 16
ChemoCentryx, Inc. - Discovery, 2016 17
ChemoCentryx, Inc. - Pipeline by Target, 2016 47
ChemoCentryx, Inc. - Pipeline by Route of Administration, 2016 48
ChemoCentryx, Inc. - Pipeline by Molecule Type, 2016 49
ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action, 2016 51
ChemoCentryx, Inc. - Dormant Developmental Projects,2016 52
ChemoCentryx, Inc. - Discontinued Pipeline Products, 2016 53
ChemoCentryx, Inc., Subsidiaries 54